Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry—a historical cohort study

Abstract Background Previous studies have shown conflicting evidence regarding the incidence of cancer in patients with systemic lupus erythematosus (SLE) compared with that in healthy individuals. Calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus have been widely used to treat SLE;...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Kunihiro Ichinose, Shuntaro Sato, Takashi Igawa, Momoko Okamoto, Ayuko Takatani, Yushiro Endo, Sosuke Tsuji, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Shin-ya Kawashiri, Naoki Iwamoto, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Nobuyuki Yajima, Ken-Ei Sada, Yoshia Miyawaki, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Shuzo Sato, Michio Fujiwara, Atsushi Kawakami
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2024-02-01
Ráidu:	Arthritis Research & Therapy
Fáttát:	Systemic lupus erythematosus Calcineurin inhibitors Cancer Propensity score IPW
Liŋkkat:	https://doi.org/10.1186/s13075-024-03285-x
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!